ES2718208T3 - Anticuerpos anti-MCAM y métodos de uso asociados - Google Patents
Anticuerpos anti-MCAM y métodos de uso asociados Download PDFInfo
- Publication number
- ES2718208T3 ES2718208T3 ES13836030T ES13836030T ES2718208T3 ES 2718208 T3 ES2718208 T3 ES 2718208T3 ES 13836030 T ES13836030 T ES 13836030T ES 13836030 T ES13836030 T ES 13836030T ES 2718208 T3 ES2718208 T3 ES 2718208T3
- Authority
- ES
- Spain
- Prior art keywords
- tracheostoma
- tubular body
- container
- tracheostomy
- tracheostoma device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title description 5
- 239000011324 bead Substances 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 210000003813 thumb Anatomy 0.000 claims description 4
- 210000003811 finger Anatomy 0.000 claims description 3
- 238000007789 sealing Methods 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 210000005224 forefinger Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698916P | 2012-09-10 | 2012-09-10 | |
| US201261797179P | 2012-11-30 | 2012-11-30 | |
| US201261797356P | 2012-12-05 | 2012-12-05 | |
| PCT/US2013/058773 WO2014039975A2 (en) | 2012-09-10 | 2013-09-09 | Anti-mcam antibodies and associated methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2718208T3 true ES2718208T3 (es) | 2019-06-28 |
Family
ID=50237783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13836030T Active ES2718208T3 (es) | 2012-09-10 | 2013-09-09 | Anticuerpos anti-MCAM y métodos de uso asociados |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US20150239980A1 (OSRAM) |
| EP (2) | EP3530287A1 (OSRAM) |
| JP (1) | JP6339574B2 (OSRAM) |
| KR (1) | KR102194568B1 (OSRAM) |
| CN (2) | CN105120895A (OSRAM) |
| AR (1) | AR092488A1 (OSRAM) |
| AU (2) | AU2013312203B2 (OSRAM) |
| CA (1) | CA2884463A1 (OSRAM) |
| CL (1) | CL2015000582A1 (OSRAM) |
| CO (1) | CO7400878A2 (OSRAM) |
| CU (1) | CU20150023A7 (OSRAM) |
| DK (1) | DK2892562T3 (OSRAM) |
| EA (1) | EA201590528A1 (OSRAM) |
| ES (1) | ES2718208T3 (OSRAM) |
| IL (1) | IL237625A0 (OSRAM) |
| MX (1) | MX2015002918A (OSRAM) |
| MY (1) | MY182427A (OSRAM) |
| PE (1) | PE20151286A1 (OSRAM) |
| PH (1) | PH12015500514A1 (OSRAM) |
| SG (2) | SG11201501773RA (OSRAM) |
| TW (3) | TW201922795A (OSRAM) |
| WO (1) | WO2014039975A2 (OSRAM) |
| ZA (1) | ZA201501858B (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| BR112013013354A2 (pt) | 2010-11-30 | 2020-10-06 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| JP6501521B2 (ja) | 2012-08-24 | 2019-04-17 | 中外製薬株式会社 | ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体 |
| TW201922795A (zh) | 2012-09-10 | 2019-06-16 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
| CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| DK3116911T3 (da) * | 2014-03-12 | 2019-09-30 | Prothena Biosciences Ltd | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse |
| TW201623331A (zh) * | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| WO2015136468A1 (en) * | 2014-03-13 | 2015-09-17 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
| WO2016022694A1 (en) * | 2014-08-05 | 2016-02-11 | The University Of Chicago | Modulation of laminin alpha-4 in the prevention, treatment, and management of metabolic syndromes |
| MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用 |
| CN104725483A (zh) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | 一种黑色素瘤细胞粘附分子拮抗剂多肽及其应用 |
| CN104710513A (zh) * | 2015-04-06 | 2015-06-17 | 苏州普罗达生物科技有限公司 | 黑色素瘤细胞粘附分子拮抗剂多肽及其应用 |
| JP2018530540A (ja) * | 2015-09-16 | 2018-10-18 | プロセナ バイオサイエンシーズ リミテッド | 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用 |
| WO2017046774A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017100670A1 (en) | 2015-12-09 | 2017-06-15 | Corvus Pharmaceuticals, Inc. | Humanized anti-cd73 antibodies |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017153953A1 (en) * | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Ｉｌ−８関連疾患の治療用又は予防用組成物 |
| WO2018223140A1 (en) * | 2017-06-02 | 2018-12-06 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2019133639A2 (en) * | 2017-12-26 | 2019-07-04 | The Regents Of The University Of California | Human antibodies that bind and are internalized by mesothelioma and other cancer cells |
| AU2019401647A1 (en) | 2018-12-21 | 2021-07-08 | Multitude Inc. | Antibodies specific to MUC18 |
| AU2019401657B2 (en) * | 2018-12-21 | 2025-10-09 | Multitude Therapeutics Inc. | Antibodies specific to MUC18 |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024243340A1 (en) | 2023-05-23 | 2024-11-28 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB1520819A (en) | 1976-05-10 | 1978-08-09 | Robertson H J | Medical protein hydrolysate process of making the same and processes of utilizing the protein hydrolysate to aid in healing traumatized areas |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5224539A (en) | 1991-06-14 | 1993-07-06 | Coen Company, Inc. | Cooling system for air heaters and the like |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| GB9406974D0 (en) | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| AU757961B2 (en) | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US7192931B2 (en) | 2000-10-12 | 2007-03-20 | Neuren Pharmaceuticals Ltd. | Treatment of demyelinating diseases |
| US6866866B1 (en) | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
| EP1379274A4 (en) * | 2001-03-23 | 2006-02-15 | Univ Texas | METHODS FOR INHIBITING ANGIOGENESIS, TUMOR GROWTH AND METASTASIS USING ANTI-HUMAN ANTI-IL8 AND ANTI-MUC18 IN VARIOUS TYPES OF TUMORS |
| WO2003005783A2 (en) | 2001-07-03 | 2003-01-16 | Sciperio, Inc. | Methods and systems for embedding electrical components in a device including a frequency responsive structure |
| TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| WO2003057838A2 (en) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| JP2005516965A (ja) | 2001-12-28 | 2005-06-09 | アブジェニックス・インコーポレーテッド | 抗ｍｕｃ１８抗体を使用する方法 |
| ES2307824T3 (es) | 2001-12-28 | 2008-12-01 | Amgen Fremont Inc. | Uso de anticuerpos contra el antigeno muc18. |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7456260B2 (en) | 2002-06-17 | 2008-11-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Humanized antibody |
| EP2365004B1 (en) * | 2002-06-21 | 2016-01-06 | Johns Hopkins University School of Medicine | Membrane associated tumor endothelium markers |
| EP1382615A1 (en) * | 2002-07-15 | 2004-01-21 | Xerion Pharmaceuticals AG | MCAM inhibitors |
| SK50642005A3 (sk) | 2003-01-24 | 2006-02-02 | Elan Pharmaceuticals, Inc. | Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok |
| UY28886A1 (es) * | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| JP5102028B2 (ja) * | 2004-07-26 | 2012-12-19 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗ｃｄ１５４抗体 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007058725A2 (en) * | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| KR20080090414A (ko) * | 2005-12-06 | 2008-10-08 | 도만티스 리미티드 | 세포 표면 표적에 대한 결합 특이성이 있는 이중 특이성리간드 및 이의 사용방법 |
| WO2009028663A1 (ja) | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-3抗体 |
| JP5620106B2 (ja) | 2007-10-24 | 2014-11-05 | 株式会社糖鎖工学研究所 | 増強されたエフェクター機能を有するポリペプチド |
| US8263743B2 (en) | 2007-11-13 | 2012-09-11 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against TL1A |
| NZ585516A (en) | 2007-12-21 | 2012-07-27 | Hoffmann La Roche | Anti-cd20 antibody formulation |
| US8155019B2 (en) * | 2008-01-07 | 2012-04-10 | Canon Kabushiki Kaisha | Information processing apparatus, device information display method, and computer-readable storage medium |
| AR070141A1 (es) | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | Anticuerpos humanizados especificos para el factor von willebrand |
| US8293468B2 (en) * | 2009-06-10 | 2012-10-23 | Centre Hospitalier De L'université De Montréal | MCAM modulation and uses thereof |
| WO2011013753A1 (ja) * | 2009-07-29 | 2011-02-03 | シスメックス株式会社 | ヒトil-17産生ヘルパーt細胞検出用マーカーおよび試薬、並びにヒトil-17産生ヘルパーt細胞の検出方法 |
| WO2011100477A2 (en) * | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| EP3072904A1 (en) | 2010-03-02 | 2016-09-28 | Abbvie Inc. | Therapeutic dll4 binding proteins |
| US8501418B2 (en) | 2010-08-06 | 2013-08-06 | Pronata N.V. | Method of treating renal dysfunction based on perlecan as a biomarker |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| UA115966C2 (uk) * | 2010-11-25 | 2018-01-25 | Аллекра Серап'Ютікс Гмбх | ЗАСТОСУВАННЯ β-ЛАКТАМНИХ СПОЛУК ДЛЯ ЛІКУВАННЯ БАКТЕРІАЛЬНИХ ІНФЕКЦІЙ АБО ЗАПОБІГАННЯ ЦИМ ІНФЕКЦІЯМ |
| JP5946605B2 (ja) * | 2011-01-28 | 2016-07-06 | シスメックス株式会社 | ヒトｉｌ−１７産生ヘルパーｔ細胞の検出方法 |
| HK1197072A1 (en) * | 2011-06-06 | 2015-01-02 | Neotope Biosciences Limited | Mcam antagonists and methods of treatment |
| AU2013221635B2 (en) | 2012-02-16 | 2017-12-07 | Santarus, Inc. | Anti-VLA1 (CD49a) antibody pharmaceutical compositions |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| TW201922795A (zh) | 2012-09-10 | 2019-06-16 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| CA2926089C (en) | 2013-10-24 | 2022-08-30 | Medimmune, Llc | Stable, aqueous antibody formulations |
| WO2015136570A1 (ja) | 2014-03-11 | 2015-09-17 | パナソニック液晶ディスプレイ株式会社 | 表示装置及びその駆動方法 |
| CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| US20170129954A1 (en) | 2014-03-12 | 2017-05-11 | Prothena Biosciences Limited | Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis |
| TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| JP2017512772A (ja) | 2014-03-12 | 2017-05-25 | プロセナ バイオサイエンシーズ リミテッド | Ｌｇ１〜３に特異的な抗ラミニン４抗体 |
| US20170101470A1 (en) | 2014-03-12 | 2017-04-13 | Prothena Biosciences Limited | Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis |
| DK3116911T3 (da) | 2014-03-12 | 2019-09-30 | Prothena Biosciences Ltd | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse |
| WO2015136468A1 (en) | 2014-03-13 | 2015-09-17 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
| JP2018530540A (ja) | 2015-09-16 | 2018-10-18 | プロセナ バイオサイエンシーズ リミテッド | 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用 |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2018223140A1 (en) | 2017-06-02 | 2018-12-06 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
-
2013
- 2013-09-06 TW TW108108483A patent/TW201922795A/zh unknown
- 2013-09-06 TW TW106116728A patent/TWI660972B/zh not_active IP Right Cessation
- 2013-09-06 TW TW102132203A patent/TWI595007B/zh not_active IP Right Cessation
- 2013-09-09 EP EP19155167.0A patent/EP3530287A1/en not_active Withdrawn
- 2013-09-09 PE PE2015000328A patent/PE20151286A1/es not_active Application Discontinuation
- 2013-09-09 EP EP13836030.0A patent/EP2892562B1/en active Active
- 2013-09-09 EA EA201590528A patent/EA201590528A1/ru unknown
- 2013-09-09 CN CN201380047188.9A patent/CN105120895A/zh active Pending
- 2013-09-09 CN CN201710411450.3A patent/CN107266571A/zh active Pending
- 2013-09-09 CA CA2884463A patent/CA2884463A1/en not_active Abandoned
- 2013-09-09 SG SG11201501773RA patent/SG11201501773RA/en unknown
- 2013-09-09 US US14/427,290 patent/US20150239980A1/en not_active Abandoned
- 2013-09-09 SG SG10201708127UA patent/SG10201708127UA/en unknown
- 2013-09-09 AU AU2013312203A patent/AU2013312203B2/en not_active Ceased
- 2013-09-09 DK DK13836030.0T patent/DK2892562T3/en active
- 2013-09-09 WO PCT/US2013/058773 patent/WO2014039975A2/en not_active Ceased
- 2013-09-09 MX MX2015002918A patent/MX2015002918A/es unknown
- 2013-09-09 AR ARP130103202A patent/AR092488A1/es unknown
- 2013-09-09 ES ES13836030T patent/ES2718208T3/es active Active
- 2013-09-09 US US14/021,777 patent/US9447190B2/en not_active Expired - Fee Related
- 2013-09-09 KR KR1020157008706A patent/KR102194568B1/ko not_active Expired - Fee Related
- 2013-09-09 MY MYPI2015700717A patent/MY182427A/en unknown
- 2013-09-09 JP JP2015531286A patent/JP6339574B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-09 CL CL2015000582A patent/CL2015000582A1/es unknown
- 2015-03-09 IL IL237625A patent/IL237625A0/en unknown
- 2015-03-10 PH PH12015500514A patent/PH12015500514A1/en unknown
- 2015-03-10 CU CUP2015000023A patent/CU20150023A7/es unknown
- 2015-03-18 ZA ZA2015/01858A patent/ZA201501858B/en unknown
- 2015-04-08 CO CO15077895A patent/CO7400878A2/es unknown
-
2016
- 2016-07-28 US US15/222,849 patent/US10414825B2/en not_active Expired - Fee Related
- 2016-07-28 US US15/222,848 patent/US10407507B2/en not_active Expired - Fee Related
-
2017
- 2017-10-05 US US15/726,170 patent/US10584177B2/en not_active Expired - Fee Related
-
2018
- 2018-10-04 AU AU2018241135A patent/AU2018241135B2/en not_active Ceased
-
2020
- 2020-01-16 US US16/745,178 patent/US20200216560A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2718208T3 (es) | Anticuerpos anti-MCAM y métodos de uso asociados | |
| ES2625327T3 (es) | Dispositivo protector de respiración | |
| ES2295552T3 (es) | Adaptador para cambiador de calor y humedad para conjunto de cateter de succion cerrado y sistema mejorado de limpieza del cateter. | |
| ES2793245T3 (es) | Protector respiratorio | |
| ES2748774T3 (es) | Portadispositivo de traqueostoma | |
| ES2730683T3 (es) | Portadispositivo de traqueostoma | |
| US9427542B2 (en) | Breathing protector | |
| US20140150779A1 (en) | Breathing protector | |
| US20110247629A1 (en) | Tracheostoma plaster | |
| ES2718230T3 (es) | Válvula de traqueostoma | |
| WO2015107320A1 (en) | Gas-treatment devices and apparatus | |
| US20250339638A1 (en) | Breathing protector | |
| CN212679079U (zh) | 隔绝呼吸道传染病用可视喉镜套 | |
| AU2017356021B2 (en) | Tracheotomy tube having freely openable/closable lateral hole | |
| CN205055112U (zh) | 一种经口人工鼻 | |
| US20110290255A1 (en) | Tracheal cannula |